Company Contact: John F. DeBernardis, Ph.D., President & CEO
Investor Contact: Ira Weingarten/Steve Chizzik
Media Contact: Jeff Siegel, Monarch Communications
Applied NeuroSolutions’ Alzheimer’s Test Expected to be Featured on “Lou Adler’s Medical Journal” Radio Report
Vernon Hills, IL, October 18, 2005 -
Applied NeuroSolutions (OTB BB: APNS; www.appliedneurosolutions.com) today announced that its Alzheimer's disease diagnostic test is scheduled to be featured on “Lou Adler's Medical Journal,” a radio report, from Wednesday through Friday of this week (October 19-21).
In the Northeast, the three-part report can be heard during “The WOR Morning Show with Ed Walsh,” the morning drive-time show on WOR-AM (710 AM), a 50,000 watt radio station. The show runs from 5:00 am – 9:00 am EDT and can be heard at http://www.wor710.com/listen.shtml.
Heard each weekday, “Lou Adler's Medical Journal” is hosted by Adler, a well-respected, veteran journalist, who discusses important medical advances. The report is syndicated through the WOR Radio Network in New York and heard on many radio stations in the United States and throughout the world on the American Forces Radio Network.
Applied NeuroSolutions, Inc. is developing products to diagnose and treat Alzheimer's disease based on a novel hypothesis of AD pathology. In partnership with Dr. Peter Davies and a scientific team at Albert Einstein College of Medicine, Applied NeuroSolutions has developed a cerebrospinal fluid (CSF) test to detect Alzheimer's disease at a very early stage with 85%-95% accuracy in more than 3,000 patient samples. There are approximately 2 million new patients annually worldwide who are candidates for an AD CSF diagnostic test, according to Datamonitor. In the U.S. alone, Datamonitor projects an $80 to $160 million annual market potential. The company is also developing a blood serum-based screening test, as well as a new class of therapeutics to treat AD. Alzheimer's disease currently afflicts over 4 million Americans, and the market for AD therapy is expected to grow to 21 million patients by 2010 in the seven major pharmaceutical markets (USA, France, Germany, Italy, Spain, U.K. and Japan) according to BioPortfolio, Ltd.
There are currently no FDA-approved diagnostic tests to detect Alzheimer's disease.
This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.